The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilian's Health Ministry is comparable to those reported in the literature;A taxa de resposta sustentada da hepatite C crônica ao tratamento com os diversos interferons-alfa e ribavirinas distribuídos pelo Governo Brasileiro é semelhante à da literatura mundial

Arquivos de Gastroenterologia

Volumn 41, Issue 1, 2004, Pages 3-9

  Acras, Rafael Nastás ^a   Pedroso, Maria Lúcia A ^a,b   Caum, Leiber Carvalho ^a   Pisani, Júlio C ^a   Amarante, Heda M B S ^a   Carmes, Eliane R ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE   (Brazil)

Author keywords

Chronic hepatitis C; Interferons; Ribavirin

Indexed keywords

ALPHA2 INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CHRONIC HEPATITIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; TREATMENT OUTCOME;

EID: 4043154079     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-28032004000100002     Document Type: Article

References (30)

1. Brasil. Ministėrio da Saúde. Portaria 639. Anexo 1: Protocolo clinico e diretrizes terapêuticas da hepatite viral crõnica tipo C. Diário Oficial da União, Brasilia, DF., 26 jun 2000. p. 34.
2. Choo Q-L, Kuo G, Weiner AJ, Overley LR, Bradley DW, Houghton M. Isolation of a cDNA clone from a blood-borne non-A non-B viral hepatitis genome. Science 1989;244:359-62.
3. Davis G. Hepatitis C. In; Schiff E, editor. Liver disease. Philadelphia: Lippincot-Raven; 1999. p.793-825.
4. Epi Info, version 6.04b. A word processíng, database and statistics program for public health [computer program]. Atlanta, GA: Centers for Disease Control & Prevention; January 1997.
5. Fergusson D, Aaron S, Guyatt G, Herbert P. Post randomization exclusions; the intention to treat principle and excluding patients from analysis. BMJ 2002;325:652-4.
6. Forns X, Ampurdanes S, Llovet J, Aponte J, Quintó L, Martinez-Bauer E, Bruguera M, Sánchez-Tapias J, Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002;36:986-92.
7. Foster GR. Pegylated Interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opin Pharmacother 2003;4;685-91.
8. Fried M, Shjffman M, Reddy R, Smith C, Marinos G, Gonçales Jr F, Haussinger D, Diago M, Caroni G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peg interferon-α-2A plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
9. Gayotto LC e Comitê SBP-SBH. Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. Projeto do Clube de Patologia Hepȧtica da Sociedade Brasileira de Patologia aprovado pela Sociedade Brasileira de Hepatologia. GED Gastroenterol Endosc Dig 2000;19;137-40.
10. Glantz S. Primer of biostatistics. 4th ed. New York: McGraw Hill; 1997.
11. Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 2000;75(3):18-9.
12. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20(1 Pt 1):15-20.
13. Kjaergard L, Krogsgaard K, Gluud C. Interferon alpha with or without ribavirin for chronic hepatitis C: systematic review of randomized trials. BMJ 2001;323:1151-5.
14. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha Interferon for chronic hepatitis C [update of: Cochrane Database Syst Rev 2002;(1):CD002234]. Cochrane Database Syst Rev 2002;(2):CD002234.
15. Kjaergard LL, Krogsgaard K, Gluud C. Ribavirin with or without alpha Interferon for chronic hepatitis C [update of: Cochrane Database Syst Rev 2002;(1):CD002234]. Cochrane Database Syst Rev 2002;(2):CD002234.
16. Koretz RL. Decisions, decisions, decísions. Gastroenterology 2000;118:1268-70.
17. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001;354:41-52.
18. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296-305.
19. Marcellin P. Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997:127:875-81.
20. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa 2B alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
21. Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, Zarski JP, Poynard T. Interferon for Interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev; (2):CD000370, 2002.
22. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C, Hepatology 1997;26(3 Suppl 1):2S-10S.
23. Pedder SC. Pegylation of Interferon alpha: structural and pharmacokinetic properties. Sem Liver Dis 2003;1 Suppl 23:19-22.
24. Poynard T, Leroy V, Cohard M. Meta analysis of Interferon randomized trials in the treatment of viral hepatitis, effects of dose and duration. Hepatology 1996;24:778-89.
25. Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G, Bain V Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomized trial of Interferon 2B plus ribavirin for 48 weeks or for 24 weeks versus Interferon 2b plus placebo for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
26. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an "a la carte" combination Interferon 2B plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31:211-8.
27. Schalm S, Weiland O, Hansen B, Milella M, Lai M, Hollander A, Michielsen P, Belloleuono A, Chemello L, Pastore G, Chen D, Brouwer J. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
28. Shepherd J, Waugh N, Hewitson P. Combination therapy (Interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review, Health Technol Assess 2000;4(33):1-67.
29. Suva LC. Drogas utilizadas no tratamento das hepatites crônicas. Alguns aspectos farmacológicos. In: Silva LC, editor. Hepatites agudas e crônicas. 2.ed. São Paulo: Sarvier;1995. p.273-81.
30. Stancek D, Fuchsberger N, Oilman M, Schmeisser H, Kontsek P, Jahnová E, Hajnická V Significance of anti-interferon-alpha2 and sICAM-1 activities in the sera of viral hepatitis B and C patients treated with human recombinant interferon-alpha2. Acta Virol 2001;45;287-92.